CHMP recommends Viteka for HIV 1
On 19 September 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Vitekta (elvitegravir, an HIV-1 integrase strand transfer inhibitor)from Gilead Sciences and intended, in combination with other agents, for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults. Inhibition of integrase by elvitegravir prevents the integration of HIV-1 DNA into host genomic DNA, blocking the for formation of the HIV-1 provirus and propagation of the viral infection.
The approved indication is: �coadministered with ritonavir-boosted protease inhibitor and with other antiretroviral agents, for the treatment of HIV-1 infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir."
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins